Login / Signup
Matters arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease.
Michel Alexander Steiner
Published in:
NPJ Parkinson's disease (2024)
Keyphrases
</>
rare case